SEA-BCMA

BIOLOGICAL2 trials

Sponsors

Cogent Biosciences, Inc., Seagen Inc.

Conditions

Multiple MyelomaMultiple Myeloma in RelapseRefractory Multiple Myeloma

Phase 1

Study of ACTR087 in Combination With SEA-BCMA in Subjects With Relapsed or Refractory Multiple Myeloma

TerminatedNCT03266692

Cogent Biosciences, Inc.Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma

Start: 2018-02-22End: 2019-10-01Updated: 2020-03-30

A Safety Study of SEA-BCMA in Patients With Multiple Myeloma

TerminatedNCT03582033

Seagen Inc.Multiple Myeloma

Start: 2018-11-01End: 2023-11-09Updated: 2024-12-24

Related Papers

Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

Blood2022-11-152 citations

SEA-BCMA, an Investigational Nonfucosylated Monoclonal Antibody: Ongoing Results of a Phase 1 Study in Patients with Relapsed/Refractory Multiple Myeloma (SGNBCMA-001)

Blood2021-11-058 citations

Pharmacodynamics of SEA-BCMA, a Nonfucosylated Antibody Targeting BCMA, in Patients with Relapsed/Refractory Multiple Myeloma

Blood2021-11-052 citations

SGNBCMA-001: A phase 1 study of SEA-BCMA, a non-fucosylated monoclonal antibody, in subjects with relapsed or refractory multiple myeloma.

Journal of Clinical Oncology2019-05-209 citations

Abstract OT2-07-06: Antibody-coupled T cell receptor (ACTR) engineered autologous T cells in combination with trastuzumab for the treatment of HER2-positive malignancies

Cancer Research2019-02-15

A Phase 1 Study of Two Investigational Agents, ACTR087, an Autologous T Cell Product Expressing an Antibody-Coupled T Cell Receptor, in Combination with SEA-BCMA, a Novel Non-Fucosylated Monoclonal Antibody, in Subjects with Relapsed or Refractory Multiple Myeloma

Blood2018-11-296 citations